A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study with Post-hoc biomarker analysis

A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibitor, in patients with mild to moderate atopic dermatitis: a proof-of-concept study with Post-hoc biomarker analysis

BackgroundCurrent guidelines to treat atopic dermatitis (AD) overlook disease heterogeneity, limiting personalized care. This study assessed NuGel, a topical GPCR19 agonist, for efficacy, safety, and predictive baseline biomarkers in AD patients.MethodsIn a multicenter, double-blind, randomized, pla...

Full description

Saved in:
Bibliographic Details
Main Authors: Gyeong Ho Baek, Bo Ri Kim, Jung-Won Shin, Chang Hun Huh, Jungjoong Hwang, Sungmin Ko, Siwon Kim, Pil-Su Ho, Kyu-Han Kim, Chun Wook Park, Seong Jun Seo, Chang-Ook Park, Dongyoon Shin, Yeongshin Kim, Youngsoo Kim, Seung-Yong Seong, Jung-Im Na
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Immunology
Subjects:
atopic dermatitis
GPCR19
inflammasome
precision medicine
taurodeoxycholic acid
clinical trial
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1560447/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1560447/full

Similar Items